European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.


The EMCDDA was set up to provide 'factual, objective, reliable and comparable information concerning drugs, drug addiction and their consequences'

European Drug Report 2022

Published by
Publication Date


The Trends and Developments report presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national data across these themes and key harm-reduction interventions.

New European mini guides on responding to drug use in specific settings by EMCDDA

Published by
Publication Date

Focusing treatments on specific settings where problems may develop is an important approach to implementing health and social responses to drug problems. As a result, the EMCDDA's Health and social solutions to drug problems: a European handbook offers a series of mini guides on the subject. The agency is releasing the first three mini guidelines in this bundle this week, which look at business, community, and recreational environments.

Women and drugs in Europe — why gender matters?


Description: This webinar will explore recent patterns and trends in drug use among women in Europe and the role played by gender in influencing women’s consumption behaviours across settings and the life course.

Wastewater analysis and drugs — a European multi-city study 2022

The analysis of municipal wastewaters for drugs and their metabolic products to estimate community consumption is a developing field, involving scientists working in different research areas, including analytical chemistry, physiology, biochemistry, sewage engineering, spatial epidemiology and statistics, and conventional drug epidemiology. This page presents the findings from studies conducted since 2011. Data from all studies can be explored through an interactive tool, and a detailed analysis of the findings of the most recent study, in

European Commission adopts measures to control two harmful new drugs amidst health concerns and surge in supply

Today, the European Commission has adopted measures to control two harmful new psychoactive substances (NPS) across the EU. The substances in question — 3-methylmethcathinone (3-MMC) and 3-chloromethcathinone (3-CMC) — are both synthetic cathinones, which have been raising concerns in Europe. The delegated act follows risk assessments conducted by the EU drugs agency (EMCDDA) in November 2021 (2) as part of a three-step legal procedure designed to respond to potentially threatening new drugs available on the